Analyst firms · Raymond James · ABT
Raymond James ABT price target and rating history
Abbott Laboratories (ABT) · Health Care
Raymond James rates Abbott Laboratories (ABT) Outperform with a $123 price target, as of its latest action on Apr 20, 2023. It has published 5 rating actions on ABT since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a ABT price target in the last 12 months, the median target is $121.
- Current rating
- Outperform
- Price target
- $123
- Median target, all firms
- $121
- Actions on ABT
- 5
Raymond James price target on ABT
Every Raymond James rating on ABT
- Apr 20, 2023
- Jan 27, 2022
- Dec 22, 2021
- Oct 21, 2021
- Jul 23, 2021
How other firms rate ABT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Hold | Oct 27, 2026 | |
| Barclays | Overweight | $120 | Oct 7, 2026 |
| Rothschild & Co Redburn | Buy | $127 | Oct 2, 2026 |
| Wolfe Research | Outperform | $130 | Aug 13, 2026 |
| Robert W. Baird | Outperform | $121 | Jul 1, 2026 |
| Daiwa | Neutral | $92 | Apr 22, 2026 |
Questions about Raymond James and ABT
- What is Raymond James's price target for ABT?
- Raymond James's latest stated price target for Abbott Laboratories (ABT) is $123, from its action on Apr 20, 2023.
- What is Raymond James's rating on ABT?
- Raymond James rates ABT Outperform, a bullish rating, as of Apr 20, 2023.
- When did Raymond James last change its view on ABT?
- On Apr 20, 2023, Raymond James raises its price target to $123 from $116, keeps Outperform.
- How does Raymond James's ABT target compare with other analysts?
- Across 5 firms with a ABT price target in the last 12 months, the median target is $121.
More ABT rating histories
All Raymond James ratingsABT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.